MEDS MEDS
Company Profile ↓Company Overview
MEDS (MEDS) is a publicly traded company listed on with a market capitalization of $5.67M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $23.34M (+28.7% YoY); net profit $-101.27M.
- Trailing 12 Months Year-on-year growth — revenue +28.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -10.70% |
| 1 Year: | 28.73% |
Stock Price Performance
| 1 Year: | -93.19% |
| 6 Months: | -84.53% |
| 3 Months: | -45.63% |
| 1 Month: | -6.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -10.7% CAGR over 5 years.
- Trading 96.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 10.86M | 7.79M | 3.01M | 1.67M | 1.56M |
| Cost of Revenue | 10.17M | 7.29M | 2.78M | 9.53M | 1.39M |
| Gross Profit | 692.64K | 505.75K | 231.01K | -7.86M | 170.22K |
| Operating Expenses | 32.04M | 6.01M | 31.78M | 4.94M | 6.19M |
| Operating Income | -31.35M | -5.50M | -31.55M | -12.80M | -6.02M |
| EBITDA | -30.53M | -4.69M | -32.09M | -26.17M | -5.31M |
| Interest Expense | 1.09M | 1.18M | 1.43M | 875.72K | 2.07M |
| Pretax Income | -32.43M | -6.67M | -34.32M | -27.85M | -7.74M |
| Tax Provision | 0 | 0 | 0 | 0 | 0 |
| Net Income | -32.43M | -6.67M | -34.32M | -27.85M | -7.74M |
| Diluted EPS | -31.00 | -5.50 | -23.00 | - | -3.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 32.78M | 0 | 18.13M | 23.34M |
| Cost of Revenue | 27.03M | 0 | 16.36M | 29.76M |
| Gross Profit | 5.75M | 0 | 1.77M | -6.43M |
| Operating Expenses | 9.17M | 2.88M | 7.91M | 74.77M |
| Operating Income | -3.42M | -2.88M | -6.15M | -81.19M |
| EBITDA | -369.03K | -2.88M | -4.91M | -93.48M |
| Interest Expense | 287.18K | 15.08K | 831.47K | 4.58M |
| Pretax Income | -2.74M | -2.90M | -6.86M | -101.27M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -2.74M | -2.90M | -6.86M | -101.27M |
| Diluted EPS | -2.90 | -3.00 | -7.50 | -71.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 0 | 338.36K | 57.33M | 30.46M |
| Current Assets | 0 | 338.36K | 15.17M | 2.82M |
| Cash & Equivalents | 0 | 1.36K | 1.03M | 42.57K |
| Inventory | - | 0 | 9.52M | 1.64M |
| Receivables | - | 0 | 2.72M | 1.14M |
| Total Liabilities | 5.25K | 3.24M | 50.60M | 42.91M |
| Current Liabilities | 5.25K | 2.89M | 38.05M | 29.78M |
| Long Term Debt | - | 350.00K | 11.46M | 12.60M |
| Total Debt | - | 350.00K | 25.11M | 24.77M |
| Total Equity | -5.25K | -2.90M | 6.73M | -12.45M |
| Shares Outstanding | 1.04M | 1.04M | 1.04M | 2.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 0 | -349.14K | -1.22M | -10.86M |
| Investing Cash Flow | - | 0 | 469.07K | -881.53K |
| Financing Cash Flow | 0 | 350.50K | 1.78M | 10.75M |
| Capital Expenditure | - | - | -377.29K | -881.53K |
| Free Cash Flow | 0 | -349.14K | -1.60M | -11.74M |
| Net Change in Cash | - | 1.36K | 1.03M | -985.76K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 17.5% | - | 9.7% | -27.5% |
| Operating Margin % | -10.4% | - | -33.9% | -347.9% |
| Net Margin % | -8.4% | - | -37.8% | -433.9% |
| ROE % | 52,262.9% | 99.8% | -101.8% | 813.6% |
| ROCE % | 65,194.8% | 112.9% | -31.9% | -11,952.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MEDS
DataMeds AI's Rural App to Draw on a 6,500+ Pharmacy Network - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPUUVvN2VoMEhnanVzODZRcmp3SFEtWlk3RUJ2YVFsSGZHUm9DUmV6bGxSc0lDOGd1TXdHQlVucGQ4ZXhTUUtxRzlJZ1ZrYWFWek1lUTQ0Uy1Wa05waHd2ODFIeW9nX3AtcDdXRGQtWi02bk5XTVBjbGJrRFdFcGhDX09wdDJVYzE4UjM2OV…
Here Comes the Next Wave of GLP-1s. They’ll Treat a Lot More Than Obesity. - Barron's
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQMVFNOWZ3dXpETl9lRWZ5MnNoRzlWcU5LNjlZalJXV1VERVRTdEN0OVI1QWZDdFpTVl9RTkxTcGhpejhtNWdkcmNjN1N5djNSajc4RXU2aGFpanhJaGZwMWhMRWE3eGZOUUk1TFhrS3JqWlFid0s2Mno4Z3BndTUwNDF3UGk3Q05SQUpTdH…
DataMEDS AI Says It Will Begin Trading Under Stock Symbol MEDS on Nasdaq on July 22 - Moomoo
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQemp3clZwakpkbnNBUHlpX3IzRVVCRVJnVE1rZWpCb01uWjJkQVhmMzJOcVNQQUJMOExjb3Z0M3RHSVRDSmx5dzdpZlBMTW9QVWpWYXI4QUY5dzRFS0ZxSENoV1VwbWU5RFRGQlB0c25XNHBtVHVsZlg3bS1EaWtZRGl6YnRoeVFCeHg1c2…
Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs - KFF Health News
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNX2diMmlJNnN1cFl0Mm1fZXhKUHllMGtVZW8xQjU2ZzBKQk16MTJsZURCTFRQTnV6Z3VsLUhrcTdVUDl4eHUwdXAwb1NZcmRlamJ2cC00OTcyTm9QREFuY3BHVzBOaVNfUG5VdTJ3S1oyR1VJQXpwd3ZFSmFTcXJOSllsdy1GS0U4RWFTOU…
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds - Fierce Biotech
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOZFdJZjNMdGpjeUc1MmhLczY0aTdKbFpYZWdiR0FuWE1ULWlMUzJxcFM2LXVaYWZqS3pGNUlMQy1yMHpoVDRRSkFlejVLSWZKN2VQSHhLYVpzaEd0V1phM1dUUTNaUG5sVW9yODEwa2pSU0hCZVMwcklBYVVKX0NCMk9yakhEc1cyNUhSNV…
DataMEDS AI Officially Begins Trading Under Stock Symbol 'MEDS' on the NASDAQ Capital Markets - ACCESS Newswire
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNVGdVMmlLWFVKdE1ZcVhIOGVyN1V3SlkwbGZEYXpnRHV4OU5qQVVMMzNRZTB3S3pGbGpqMDZWclh0YmIzb2ZPX01TcXpaRWtjd3hxWWRmRVNoS1VtbHJXbmR3NElEQUsydXliZ1JOeU5wZUVqS0xzbkRlV0ZmTmlhaW1pcGgzRFZGS0Q4UE…
MEDS — Frequently Asked Questions
What is the current share price of MEDS?
As of 2026-08-05 17:25 PDT, MEDS trades at $2.80 on NASDAQ/NYSE. Its 52-week range is $2.65 to $86.50.
What is the market capitalisation of MEDS?
MEDS has a market capitalisation of $5.67M on NASDAQ/NYSE.
What is the P/E ratio of MEDS?
MEDS trades at a trailing price-to-earnings (P/E) ratio of -0.04. Its price-to-book (P/B) ratio is -0.46.
Is MEDS a good stock to buy?
This page provides a data-driven analysis of MEDS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.